| Drug Name |
Letrozole |
| Drug ID |
BADD_D01257 |
| Description |
Letrozole, or CGS 20267, is an oral non-steroidal type II aromatase inhibitor first described in the literature in 1990.[A190543,A1559,L11623,L11626] It is a third generation aromatase inhibitor like [exemestane] and [anastrozole], meaning it does not significantly affect cortisol, aldosterone, and thyroxine.[A190546]
Letrozole was granted FDA approval on 25 July 1997.[L11623] |
| Indications and Usage |
Letrozole is indicated to treat postmenopausal women with hormone receptor (HR) positive early breast cancer, postmenopausal women with early breast cancer who have periviously been treated with tamoxifen, and postmenopausal women with HR+ or unknown advanced breast cancer.[L11623] Letrozole, given with ribociclib, is indicated to treat pre, peri, and postmenopausal women with HR+ and human epidermal growth factor 2 (HER2) negative advanced or metastatic breast cancer.[L11626] |
| Marketing Status |
approved; investigational |
| ATC Code |
L02BG04 |
| DrugBank ID |
DB01006
|
| KEGG ID |
D00964
|
| MeSH ID |
D000077289
|
| PubChem ID |
3902
|
| TTD Drug ID |
D0C1WH
|
| NDC Product Code |
58623-0099; 62135-491; 63629-7819; 71205-587; 69988-0014; 50268-476; 68554-0039; 16729-034; 51991-759; 59651-180; 63850-0025; 57884-0011; 65096-0116; 13808-514; 63592-3376; 65129-1130; 0078-0249; 55111-809; 63850-7723; 0093-7620; 42291-374; 71335-1526; 63850-7701; 55111-646 |
| UNII |
7LKK855W8I
|
| Synonyms |
Letrozole | 4,4'-(1H-1,2,4-triazol-1-yl-methylene)-bis(benzonitrile) | CGS 20267 | CGS-20267 | CGS20267 | Femara | Fémara |
